Why the study?
Does a panel of 4 circulating microRNAs (miR-16, miR-27a, miR-101, miR-150) improve the prediction of impaired left ventricular contractility at 6 months in patients after acute myocardial infarction?
Does a panel of 4 circulating microRNAs (miR-16, miR-27a, miR-101, miR-150) improve the prediction of impaired left ventricular contractility at 6 months in patients after acute myocardial infarction?
A panel of 4 circulating microRNAs measured at hospital discharge improves the prediction of left ventricular dysfunction at 6 months post-AMI compared to clinical variables and NT-proBNP alone.
May improve post-AMI LV dysfunction prediction beyond clinical variables; hypothesis-generating and requires prospective validation before adoption.
BACKGROUND: Prediction of clinical outcome after acute myocardial infarction (AMI) is challenging and would benefit from new biomarkers. We investigated the prognostic value of 4 circulating microRNAs (miRNAs) after AMI. METHODS: We enrolled 150 patients after AMI. Blood samples were obtained at discharge for determination of N-terminal pro-brain natriuretic peptide (Nt-proBNP) and levels of miR-16, miR-27a, miR-101 and miR-150. Patients were assessed by echocardiography at 6 months follow-up and the wall motion index score (WMIS) was used as an indicator of left ventricular (LV) contractility. We assessed the added predictive value of miRNAs against a multi-parameter clinical model including Nt-proBNP. RESULTS: Patients with anterior AMI and elevated Nt-proBNP levels at discharge from the hospital were at high risk of subsequent impaired LV contractility (follow-up WMIS>1.2, n = 71). A combination of the 4 miRNAs (miR-16/27a/101/150) improved the prediction of LV contractility based on clinical variables (P = 0.005). Patients with low levels of miR-150 (odds ratio [95% confidence interval] 0.08 [0.01-0.48]) or miR-101 (0.19 [0.04-0.97]) and elevated levels of miR-16 (15.9 [2.63-95.91]) or miR-27a (4.18 [1.36-12.83]) were at high risk of impaired LV contractility. The 4 miRNA panel reclassified a significant proportion of patients with a net reclassification improvement of 66% (P = 0.00005) and an integrated discrimination improvement of 0.08 (P = 0.001). CONCLUSION: Our results indicate that panels of miRNAs may aid in prognostication of outcome after AMI.
No takes yet. Share an insight, caveat, or question.
Devaux et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: